ADMA Biologics Inc $ADMA Shares Purchased by Intech Investment Management LLC

Key Points

• Intech Investment Management LLC increased its stake in ADMA Biologics by 164.2%, owning approximately 292,595 shares valued at $5.8 million.
• Institutional and hedge fund investors now hold 75.68% of ADMA Biologics' total stock.
• ADMA Biologics reported quarterly earnings of $0.15 per share, surpassing analyst estimates, with a revenue of $121.98 million, reflecting a 13.8% year-over-year growth.

Intech Investment Management LLC grew its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 164.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 292,595 shares of the biotechnology company's stock after buying an additional 181,839 shares during the period. Intech Investment Management LLC owned 0.12% of ADMA Biologics worth $5,805,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ADMA. New York State Teachers Retirement System boosted its position in ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after buying an additional 108,800 shares during the period. Vident Advisory LLC purchased a new position in ADMA Biologics in the 1st quarter valued at approximately $2,735,000. Caxton Associates LLP purchased a new position in ADMA Biologics in the 1st quarter valued at approximately $668,000. GAMMA Investing LLC boosted its position in ADMA Biologics by 251.6% in the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after buying an additional 4,715 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in ADMA Biologics in the 1st quarter valued at approximately $201,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Up 0.2%

Shares of ADMA traded up $0.03 during midday trading on Wednesday, reaching $15.72. The stock had a trading volume of 594,586 shares, compared to its average volume of 3,123,486. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company's fifty day simple moving average is $17.38 and its two-hundred day simple moving average is $18.96. The company has a market cap of $3.75 billion, a price-to-earnings ratio of 18.31 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the business earned $0.13 EPS. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. Equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.